| |
Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and trispecific antibodies. Download our white paper to explore advances in cancer immunotherapy and learn how Premier Research can maximize the potential of your program throughout the development lifecycle.
|
|
Today’s Big NewsMay 22, 2024 |
| By Nick Paul Taylor Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification vision. The upfront payment has secured Biogen a deal to buy Human Immunology Biosciences (HI-Bio), a biotech that is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications. |
|
|
|
By James Waldron A month after Evotec first alluded to a “strategic reset” to rebalance the company, the German biotech has revealed the end of its gene therapy aspirations. |
By Annalee Armstrong The obesity business is cutthroat these days. AstraZeneca is taking no chances on missing out on the next big thing. The U.K. pharma is one of the first investors in a new biotech emerging today with $110 million to develop new therapies for healthy weight loss. |
By James Waldron Boehringer Ingelheim is handing over a total of 38.8 million euros ($42 million) to longtime partner OSE Immunotherapeutics for a preclinical anti-PD1/cytokine drug as well as to expand their existing solid tumor work into cardio-renal-metabolic diseases. |
|
One major hurdle in therapeutic development is the risk for unwanted immunogenicity, which can lead to decreased efficacy and safety. Gain insight into available tools and de-risk your pipeline - Join your colleagues to discuss on May 22
|
|
By Nick Paul Taylor Rezolute has posted midphase data on its oral eye disease drug candidate, sparking a share price jump as investors assessed its chances of rivaling Bayer and Regeneron’s injectable Eylea for the diabetic macular edema market. |
By Helen Floersh Immunology startup Parallel Bio has released a model of the human immune system that is said to capture the way immunotherapies affect the body more accurately than animals. The so-called “Clinical Trial in a Dish” can purportedly save drug companies up to $1 billion and more than six years of development time. |
By Helen Floersh The Catalogue of Somatic Mutations in Cancer's 100th version adds more than 307,000 new gene variants, with an emphasis on RAS and BRAF mutations. |
By Conor Hale The test is designed to be performed between 11 and 14 weeks into pregnancy and delivers a risk score for developing the condition before 34 weeks. |
By Fraiser Kansteiner In its quest to reach more than 200,000 patients with its medicines in low- and middle-income countries (LMICs) by 2033, BMS is embarking on a 10-year access effort. |
Fierce podcastsDon’t miss an episode |
| | This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
